RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-746-05

This recall is currently active, issued March 19, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
February 28, 2025
Posted
March 19, 2025
Recall Number
D-0271-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
11,125 bottles.
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Distribution

Nationwide

Lot / Code Info

Lot#: 240098C, Expiration: 01/2027.

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls